金城医药
(300233)
| 流通市值：58.58亿 | | | 总市值：60.50亿 |
| 流通股本：3.72亿 | | | 总股本：3.84亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,932,025,566.29 | 1,360,240,655.35 | 721,919,205.16 | 3,373,387,400.67 |
| 营业收入 | 1,932,025,566.29 | 1,360,240,655.35 | 721,919,205.16 | 3,373,387,400.67 |
| 二、营业总成本 | 1,891,362,105.7 | 1,309,982,354.22 | 682,091,200.85 | 3,103,164,108.88 |
| 营业成本 | 1,232,102,059.3 | 868,771,753.18 | 475,205,404.72 | 2,019,599,405.01 |
| 税金及附加 | 27,146,432.33 | 17,975,972.19 | 9,250,592.83 | 39,270,519.84 |
| 销售费用 | 240,612,485 | 160,343,056.86 | 74,794,902.94 | 496,387,128.75 |
| 管理费用 | 276,986,607.8 | 187,935,873.23 | 90,172,148.26 | 378,462,118.25 |
| 研发费用 | 111,830,849.91 | 73,906,078.93 | 32,823,976.17 | 170,343,707.78 |
| 财务费用 | 2,683,671.36 | 1,049,619.83 | -155,824.07 | -898,770.75 |
| 其中:利息费用 | 8,524,621.28 | 6,055,193.5 | 3,364,620.19 | 18,478,065.59 |
| 其中:利息收入 | 5,410,746.72 | 3,927,714.06 | 2,394,201.07 | 12,898,144.23 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -108,724.65 | -143,866.15 | -714.83 | 86,537.6 |
| 加:投资收益 | 961,429.24 | 967,435.41 | 817,894.85 | -1,665,130.72 |
| 资产处置收益 | -388,847.35 | -388,847.35 | -396,165.76 | 1,454,864.3 |
| 资产减值损失(新) | -17,860,007.5 | -8,134,729.93 | -2,760,402.18 | -32,634,926.91 |
| 信用减值损失(新) | 12,203,448.98 | 8,574,187.25 | 7,015,544.06 | 1,397,494.56 |
| 其他收益 | 17,414,312.81 | 10,984,825.31 | 5,588,626.32 | 28,276,042.26 |
| 四、营业利润 | 52,885,072.12 | 62,117,305.67 | 50,092,786.77 | 267,138,172.88 |
| 加:营业外收入 | 247,970.1 | 139,296.6 | 38,759.75 | 3,846,482.49 |
| 减:营业外支出 | 2,555,207.11 | 2,471,622.62 | 331,563.68 | 2,536,632.21 |
| 五、利润总额 | 50,577,835.11 | 59,784,979.65 | 49,799,982.84 | 268,448,023.16 |
| 减:所得税费用 | 16,979,757.39 | 14,818,901.9 | 13,501,079.18 | 60,712,679.03 |
| 六、净利润 | 33,598,077.72 | 44,966,077.75 | 36,298,903.66 | 207,735,344.13 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 33,598,077.72 | 44,966,077.75 | 36,298,903.66 | 207,735,344.13 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 31,577,078.65 | 43,383,223.56 | 35,054,760.33 | 196,780,752.11 |
| 少数股东损益 | 2,020,999.07 | 1,582,854.19 | 1,244,143.33 | 10,954,592.02 |
| 扣除非经常损益后的净利润 | 21,909,810.49 | 38,730,480.06 | 32,952,569.73 | 179,904,473.7 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.08 | 0.11 | 0.09 | 0.52 |
| (二)稀释每股收益 | 0.08 | 0.11 | 0.09 | 0.52 |
| 八、其他综合收益 | -33,584.91 | -2,100,000 | - | 23,268,580.25 |
| 归属于母公司股东的其他综合收益 | -33,584.91 | -2,100,000 | - | 23,268,580.25 |
| 九、综合收益总额 | 33,564,492.81 | 42,866,077.75 | 36,298,903.66 | 231,003,924.38 |
| 归属于母公司股东的综合收益总额 | 31,543,493.74 | 41,283,223.56 | 35,054,760.33 | 220,049,332.36 |
| 归属于少数股东的综合收益总额 | 2,020,999.07 | 1,582,854.19 | 1,244,143.33 | 10,954,592.02 |
| 公告日期 | 2025-10-27 | 2025-08-21 | 2025-04-29 | 2025-03-28 |
| 审计意见(境内) | | | | 标准无保留意见 |